Recall Register

Drug recall: Tirofiban Hydrochloride Injection 5 mg/100 mL (50 mcg/mL), 100 mL single-dose container (bag), Rx only, Manufactured…

Class II FDA enforcement event 96718. Recall start date: . Status in the FDA record: Ongoing.

Reason for recall, in the words of FDA

Out-of-Specification test results were obtained in at long term conditions during 3 month's stability study for related substances.

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

Eugia US LLC started this drug recall on 21 Apr 2025. The firm address in the FDA record is in East Windsor, NJ. FDA put the recall in Class II. FDA event 96718 has 2 product records. The first FDA enforcement report date is 7 May 2025. The record gives the status Ongoing.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

USA nationwide.

Recalling firm

Eugia US LLC, East Windsor, NJ.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

2 product records in the event.

FDA event 96718: product records
Recall numberProductQuantityClassStatusReport date
D-0389-2025Tirofiban Hydrochloride Injection 5 mg/100 mL (50 mcg/mL), 100 mL single-dose container (bag), Rx only, Manufactured in India for: Eugia U.S. LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ 08520, NDC 55150-429-0118,867 bagsClass IIOngoing7 May 2025
D-0390-2025Tirofiban Hydrochloride Injection 12.5 mg/250 mL (50 mcg/mL), 250 mL single-dose container (bag), Rx only, Manufactured in India for: Eugia U.S. LLC, 279 Princeton-Hightstown Rd., E. Windsor, NJ 08520, NDC 55150-430-01Class IIOngoing7 May 2025

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Drug events that started in 2025
322
Share of these events in Class II
79%
Product records in this event
2Median of the firm: 1
Events of the firm on the register
15

Other events of the firm

Other FDA enforcement events of Eugia US LLC
InitiatedProduct (first record)TypeClassRecords
18 May 2026Lidocaine HCl Injection, USP 2%, 40 mg/2 mL (20 mg/mL), 2 mL per Single-Dose Vial, Rx Only, Mfd. in India for: Eugia US DrugClass III1
29 May 2025Gentamicin Injection, USP, (PEDIATRIC), 20 mg per 2 mL (10 mg per mL*), 2 mL Single-Dose Vial, Rx Only, Mfd. in India foDrugClass II1
10 Apr 2025Testosterone Cypionate Injection, USP, CIII, 200mg per mL, Rx only, 1mL Single-Dose Vial, Distributed by Eugia US LLC, EDrugClass II1
27 Dec 2024Progesterone Injection USP, 500mg per 10 mL (50mg/mL), 10 mL Multiple Dose Vial, Rx Only, Mfd. in India for: Eugia US LLDrugClass II1
18 Dec 2024medroxyPROGESTERone Acetate Injectable Suspension, USP, 150mg per mL, Rx only, 1 mL Single-Dose Vial, Mfd in India for: DrugClass II1
26 Jul 2024Progesterone Injection, USP, 500 mg per 10 mL (50mg/mL), 10 mL Multiple-Dose Vial, Rx Only, Mfd. in India for: Eugia US DrugClass II1
23 May 2024Dexamethasone Sodium Phosphate injection USP, 120mg per 30mL (4mg/mL), 30 mL Multiple-Dose Vial, Rx only, Distributed byDrugClass II1
22 May 2024Eptifibatide injection 20mg/10mL (2mg/mL), 10mL Single-Dose Vial, Rx only, Mfd. In India for: AuroMedics Pharma, LLC, E.DrugClass III1
22 Feb 2024Tobramycin for Injection, USP, 1.2 grams per Pharmacy Bulk Package, Rx Only, For Intravenous Use, PHARMACY BULK PACKAGE DrugClass II1
20 Feb 2024Methylprednisolone acetate Injectable Suspension, USP, 400mg per 5mL (80mg/mL, 5mL Multiple-Dose Vial, Rx only, Mfd. in DrugClass II1

Eugia US LLC: all 15 events

Official channels

Cite this page

Recall Register. FDA enforcement event 96718. https://recallregister.com/fda/ii/96718/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: USA nationwide.
What quantity of product is in FDA event 96718?
The event has 2 product records. The first record gives this quantity: 18,867 bags
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2025 have the same class?
79% of the 322 drug events that started in 2025 are in Class II.